Vertex Pharmaceuticals shared its earnings call, showing a 12% sales increase in Q3 2026.

Nov 2, 2026, 5:49 PM ETResultsRead the original at Benzinga

Good for VRTX

Vertex's Q3 sales grew 12%, and it raised its 2026 revenue forecast to $13.15 billion to $13.25 billion. Its planned kidney business still awaits a decision, but current sales and the higher forecast support a positive reading.

VRTX · Vertex Pharmaceuticals

AI read · Good for VRTX

The AI's read

The higher company forecast follows sales from its cystic fibrosis treatments and newer medicines. Casgevy and Journavix added sales, and Palsonify contributed after the acquisition. Vertex's planned kidney business still depends on a regulatory decision later this month.

Get alerts for VRTX

Follow Vertex Pharmaceuticals (VRTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VRTX

Free on the App Store and Google Play, or on the web.